12.2 Life-Threatening Oncologic Emergencies

12.2 Life-Threatening Oncologic Emergencies

Clinical Scenario: A 22-year-old male with Burkitt lymphoma receives his first cycle of multi-agent chemotherapy. Fourteen hours later, his cardiac monitor displays new peaked T waves and sinus bradycardia at 48 bpm. Labs: potassium 6.6 mEq/L, phosphorus 7.2 mg/dL, uric acid 12.4 mg/dL, creatinine 2.8 mg/dL (baseline 0.9 mg/dL), and total calcium 6.4 mg/dL (ionized calcium 0.92 mmol/L). Urine output is 10 mL/hr over two hours. The acute care nurse practitioner must recognize Clinical Tumor Lysis Syndrome and initiate rapid medical stabilization.

Tumor Lysis Syndrome (TLS): Cairo-Bishop Criteria

TLS is an oncologic emergency caused by rapid cytolysis of malignant cells (Burkitt lymphoma, high-grade non-Hodgkin lymphomas, ALL), releasing intracellular nucleic acids, potassium, and phosphates into the systemic circulation.

Cairo-Bishop Diagnostic Classification

TLS Prophylaxis & Emergency Pharmacotherapy

• Hydration: Isotonic crystalloid ($2.5–3.0\text{ L/m}^2/\text{day}$ or $200–300\text{ mL/hr}$) targeting urine output $\ge 80–100\text{ mL/m}^2/\text{hr}$ ($\ge 2\text{ mL/kg/hr}$).
• Alkalinization Obsolete: Sodium bicarbonate infusion is no longer recommended; high urinary pH ($>7.0$) precipitates calcium-phosphate salts in renal tubules, accelerating nephrocalcinosis and worsening hypocalcemia.
• Rasburicase (Recombinant Urate Oxidase): Dosed at $0.2\text{ mg/kg IV}$ daily (or pragmatic single dose $3–6\text{ mg IV}$). Rasburicase enzymatically degrades uric acid to allantoin (5–10 times more soluble). Reduces uric acid within 4 hours.
  • Contraindication: Strictly contraindicated in glucose-6-phosphate dehydrogenase (G6PD) deficiency; inability to detoxify hydrogen peroxide byproduct triggers severe methemoglobinemia and fatal hemolytic anemia.
  • Lab Handling: Blood for uric acid monitoring must be collected in pre-chilled heparinized tubes and submerged in ice water immediately to prevent in vitro enzymatic degradation.
• Allopurinol: Xanthine oxidase inhibitor blocking new uric acid synthesis. Used for prophylaxis in low/intermediate-risk disease; does not degrade pre-existing uric acid.
• Electrolyte Management:
  • Shift potassium intracellularly with IV insulin/dextrose and nebulized albuterol. Potassium binders assist removal and do not replace immediate cardioprotection or dialysis when indicated.
  • Hypocalcemia Trap: Withhold IV calcium in asymptomatic hypocalcemia to prevent calcium-phosphate precipitation ($[\text{Ca}] \times [\text{PO}_4] > 60\text{ mg}^2/\text{dL}^2$) in renal parenchyma and myocardium. Give IV calcium gluconate (1–2 g with ECG monitoring) for hyperkalemic ECG changes or symptomatic hypocalcemia. Do not wait for sine-wave widening or replace calcium merely to normalize asymptomatic hypocalcemia.
  • Obtain urgent nephrology assessment for refractory electrolyte abnormalities or oliguric AKI. Select intermittent dialysis or CRRT according to urgency, ongoing solute release and hemodynamic stability.

Hypercalcemia of Malignancy (HCM)

Hypercalcemia occurs via humoral secretion of PTHrP (80%, squamous cell lung, head/neck, and renal cancers), local osteolytic metastasis (20%, breast cancer, myeloma), or tumoral 1,25-(OH)2D production (lymphomas).

• Presentation: Lethargy, confusion, hyporeflexia, obstipation, and polyuria/dehydration. ECG shows marked QT interval shortening, PR prolongation, and Osborn (J) waves.
• Calculation: $\text{Corrected Ca (mg/dL)} = \text{Measured Ca} + 0.8 \times [4.0 - \text{Albumin (g/dL)}]$.

Emergency Management Sequence

1. 0.9% Normal Saline: Bolus 1–2 L, then $200–300\text{ mL/hr}$ to expand volume, enhance GFR, and promote calciuresis. Titrate to perfusion and overload risk. Reserve a loop diuretic for fluid overload after repletion.
2. Calcitonin: $4–8\text{ units/kg SC/IM q12h}$. Rapid onset (lowers calcium by $1–2\text{ mg/dL}$ in 2–4 hr); limited by receptor down-regulation (tachyphylaxis within 48 hr). Bridges to bisphosphonates.
3. Bisphosphonates: Inhibit osteoclastic resorption. Zoledronic acid is commonly 4 mg IV (onset 48–72 hours, nadir 4–7 days). Assess renal function first: if CrCl<60 mL/min, use renal dosing and infuse over 30–60 minutes. Severe renal impairment requires individualized specialist selection, often favoring denosumab. Pamidronate is an alternative with renal dosing and a longer infusion.
4. Denosumab: Fully human monoclonal antibody targeting RANKL (120 mg SC on day 1, with additional doses on days 8 and 15, then day 29 and every 4 weeks thereafter). An option when renal impairment limits bisphosphonates or hypercalcemia persists despite them. Monitor closely for hypocalcemia, especially with advanced kidney disease.
5. Corticosteroids: Prednisone 40–60 mg PO daily for 1,25-(OH)2D-mediated hypercalcemia in lymphoma.

Superior Vena Cava (SVC) Syndrome

SVC syndrome results from extrinsic compression or thrombosis of the superior vena cava (lung cancer, lymphoma, central catheters).

• Signs: Facial and periorbital edema, facial plethora, collateral chest wall veins, dyspnea, orthopnea, stridor (laryngeal edema), and headache.
• Pemberton's Sign: Facial flushing, cyanosis, and dyspnea when raising both arms above head for 60 seconds due to thoracic inlet congestion.
• Management: Elevate head of bed ($>45^\circ$); oxygen; urgent oncology assessment; glucocorticoids may help selected steroid-sensitive tumors, but obtain tissue diagnosis first when clinically safe; urgent endovascular stenting for acute airway compromise or cerebral edema; radiation or chemotherapy by tumor histology.

Malignant Spinal Cord Compression (MSCC)

Metastatic epidural cord compression (prostate, breast, lung, myeloma, renal cell) causes cord ischemia and irreversible paraplegia if untreated.

• Signs: Progressive localized back pain worse when supine (nocturnal, from epidural venous engorgement), followed by leg weakness, hyperreflexia, positive Babinski, sensory level, and urinary retention with overflow incontinence.
• Diagnostics: Urgent whole-spine MRI, as soon as possible and within 24 hours. Multiple levels may be involved.
• Therapy: Immediately infuse dexamethasone (bolus $10–16\text{ mg IV}$, then $4\text{ mg IV q6h}$). Urgently consult spine surgery and radiation oncology. Select decompression, stabilization and/or radiotherapy using neurologic status, spinal stability and cancer features.

Bone Marrow and Hematopoietic Stem-Cell Transplantation

Hematopoietic stem cells may come from bone marrow, peripheral blood or cord blood. Autologous transplantation returns the patient's cells; allogeneic transplantation uses donor cells and adds graft-versus-host disease (GVHD) risk. Conditioning and delayed immune recovery create major infection and cytopenia hazards. A transplant recipient with fever needs prompt evaluation and, when neutropenic, the febrile-neutropenia emergency pathway. After allogeneic transplantation, new rash, diarrhea or liver dysfunction can indicate GVHD, infection or drug toxicity and needs urgent transplant-team assessment. Painful hepatomegaly, fluid retention/weight gain, ascites and jaundice raise concern for hepatic sinusoidal obstruction syndrome. Use transplant-specific diagnostic and treatment pathways rather than assuming every complication is ordinary sepsis.

Febrile Neutropenia: Diagnostic Triage & Monotherapy

• Definition: Absolute Neutrophil Count (ANC) $<500/\mu\text{L}$ (or predicted nadir $\le 500/\mu\text{L}$) PLUS single oral temperature $\ge 38.3^\circ\text{C}$ ($101.0^\circ\text{F}$) or $\ge 38.0^\circ\text{C}$ ($100.4^\circ\text{F}$) sustained $>1\text{ hr}$. $\text{ANC} = \text{WBC} \times [(\%\text{Segmented Neutrophils} + \%\text{Bands}) / 100]$
• Danger: Neutropenic patients cannot generate pus; fever may be the sole manifestation of fulminant Gram-negative septicemia (Pseudomonas aeruginosa).
• Emergency Management: Medical emergency requiring empiric IV antipseudomonal monotherapy within 60 minutes of presentation after obtaining blood cultures (peripheral and central lines):
  • Cefepime: $2.0\text{ g IV q8h}$, OR
  • Piperacillin-Tazobactam: $4.5\text{ g IV q6h}$ (or extended 4-hr infusion), OR
  • Meropenem: $1.0\text{ g IV q8h}$ (an important option when resistant gram-negative pathogens are likely). Adjust antibiotic dosing for kidney function.
• Vancomycin Indications: Add vancomycin ($15–20\text{ mg/kg IV}$) for hemodynamic instability, suspected serious catheter or skin/soft-tissue infection, pneumonia, or suspected/proven resistant Gram-positive infection. Do not add it for mucositis alone when cefepime, meropenem or piperacillin-tazobactam provides adequate coverage. Reassess when cultures return. Avoid rectal exams or suppositories.